模拟禁食饮食联合标准抗癌治疗出现的卓越肿瘤缓解:NCT03340935试验亚组分析
该文为Ib期NCT03340935试验的亚组分析,纳入101例不同类型肿瘤患者,评估周期性模拟禁食饮食联合标准抗癌治疗的安全性和可行性。在101例患者中识别出5例晚期预后不良的实体瘤患者(广泛期小细胞肺癌1例、转移性胰腺腺癌1例、转移性结直肠癌1例、转移性三阴性乳腺癌2例),在接受周期性模拟禁食饮食联合标准全身治疗后获得完全且持久的肿瘤缓解。作者认为这些卓越缓解提示应启动临床试验,在特定临床情境下研究周期性模拟禁食饮食联合标准抗癌治疗。
要点
- NCT03340935试验纳入101例不同肿瘤类型患者,显示严重热量限制的模拟禁食饮食方案联合标准治疗安全可行。
- 5例晚期预后不良实体瘤患者经周期性模拟禁食饮食联合标准全身治疗后获得完全且持久的肿瘤缓解。
- 作者认为这些卓越缓解提示应启动临床试验研究周期性模拟禁食饮食联合标准抗癌治疗。
核心结论
- 5例晚期预后不良实体瘤患者在接受周期性模拟禁食饮食联合标准全身治疗后获得完全且持久的肿瘤缓解,作者认为这些卓越缓解提示应启动临床试验研究该联合方案。
研究设计与样本
- 本文为Ib期NCT03340935试验的亚组分析,该试验共纳入101例不同肿瘤类型的患者。
- NCT03340935试验显示严重热量限制的模拟禁食饮食方案在同时接受标准抗癌治疗的患者中安全可行。
- 周期性模拟禁食饮食可引起正向的代谢和免疫学改变,重现了临床前模型中介导禁食/模拟禁食饮食抗肿瘤效应的生物学作用。
主要发现
- 在101例入组患者中识别出5例晚期预后不良实体瘤患者获得完全且持久的肿瘤缓解。
- 5例患者分别为广泛期小细胞肺癌1例、转移性胰腺腺癌1例、转移性结直肠癌1例、转移性三阴性乳腺癌2例。
- 上述5例患者均接受周期性模拟禁食饮食联合标准全身治疗。
临床怎么用
- 作者认为这些卓越缓解提示应启动临床试验,在特定临床情境下研究周期性模拟禁食饮食联合标准抗癌治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cyclic fasting or calorie-restricted, low-carbohydrate, low-protein diets, collectively referred to as fasting-mimicking diets (FMDs), demonstrated additive or synergistic antitumour effects when combined with chemotherapy, targeted therapies, or immunotherapy in several preclinical in vivo models, including murine models of breast cancer, lung cancer, and colorectal cancer. However, no data on the antitumour efficacy of cyclic FMD in patients with cancer have been published so far. Here, we aim at reporting on patients with advanced cancer achieving complete and long-lasting tumour remissions with cyclic FMD in combination with standard anticancer therapies in the context of the phase Ib NCT03340935 trial. PATIENTS AND METHODS: The NCT03340935 trial enrolled 101 patients with different tumour types, and it showed that a severely calorie-restricted FMD regimen is safe and feasible in patients with cancer receiving concomitant standard-of-care antineoplastic therapies. In addition, cyclic FMD resulted in positive metabolic and immunologic modifications, thus recapitulating the biological effects that in preclinical models were found to mediate the antitumour effects of fasting/FMD. RESULTS: Of the 101 patients enrolled in the NCT03340935 trial, we identified five patients with advanced, poor prognosis solid neoplasms (n = 1: extensive stage small cell lung cancer; n = 1: metastatic pancreatic adenocarcinoma; n = 1: metastatic colorectal cancer; n = 2: metastatic triple-negative breast cancer), who achieved complete and long-lasting tumour responses when treated with a combination of cyclic FMD and standard systemic treatments in the context of the NCT03340935 trial. CONCLUSION: These excellent responses prompt the initiation of clinical trials to investigate cyclic FMD in combination with standard antitumour therapies in specific clinical contexts.
引用
- Ligorio F, Fucà G, Provenzano L, et al. Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial. Eur J Cancer. 2022. PMID: 35810555. doi:10.1016/j.ejca.2022.05.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。